Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-VUMC-CCA-03-02-2016-12:25:24:488-68 - samples

ABSTRACT: Paired-end whole exome sequenncing (Illumina) of primary enucleated retinoblastoma and matching lymphocyte DNA was performed to find somatic alterations that are related to oncogenesis.

PROVIDER: EGAD00001001909 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.

Kooi Irsan E IE Mol Berber M BM Massink Maarten P G MP Ameziane Najim N Meijers-Heijboer Hanne H Dommering Charlotte J CJ van Mil Saskia E SE de Vries Yne Y van der Hout Annemarie H AH Kaspers Gertjan J L GJ Moll Annette C AC Te Riele Hein H Cloos Jacqueline J Dorsman Josephine C JC

Scientific reports 20160429

Retinoblastoma is a rare childhood cancer initiated by RB1 mutation or MYCN amplification, while additional alterations may be required for tumor development. However, the view on single nucleotide variants is very limited. To better understand oncogenesis, we determined the genomic landscape of retinoblastoma. We performed exome sequencing of 71 retinoblastomas and matched blood DNA. Next, we determined the presence of single nucleotide variants, copy number alterations and viruses. Aside from ...[more]

PMID: 27126562

Similar Datasets

Copy number profiling of primary samples and cell lines of retinoblastoma

Project description:Illumina SNP-arrays for matching retinoblastoma-blood pairs and retinoblastoma cell lines.

| EGAD00010000908 | EGA

VUMC-CCA

Project description:Organisation EGAO00000000195

| EGAO00000000195 | EGA

Proceedings of the 2016 China Cancer Immunotherapy Workshop : Beijing, China. 25-26 June 2016

Project description:Table of contents A1 Proceedings of 2016 China Cancer Immunotherapy Workshop, Beijing, China Bin Xue, Jiaqi Xu, Wenru Song, Zhimin Yang, Ke Liu, Zihai Li A2 Set the stage: fundamental immunology in forty minutes Zihai Li A3 What have we learnt from the anti-PD-1/PD-L1 therapy of advanced human cancer? Lieping Chen A4 Immune checkpoint inhibitors in lung cancer Edward B. Garon A5 Mechanisms of response and resistance to checkpoint inhibitors in melanoma Siwen Hu-Lieskovan A6 Checkpoint inhibitor immunotherapy in lymphoid malignancies Wei Ding A7 Translational research to improve the efficacy of immunotherapy in genitourinary malignancies Chong-Xian Pan A8 Immune checkpoint inhibitors in gastrointestinal malignancies Weijing Sun A9 What’s next beyond PD-1/PDL1? Yong-Jun Liu A10 Cancer vaccines: new insights into the oldest immunotherapy strategy Lei Zheng A11 Bispecific antibodies for cancer immunotherapy Delong Liu A12 Updates on CAR-T immunotherapy Michel Sadelain A13 Adoptive T cell therapy: personalizing cancer treatment Cassian Yee A14 Immune targets and neoantigens for cancer immunotherapy Rongfu Wang A15 Phase I/IIa trial of chimeric antigen receptor modified T cells against CD133 in patients with advanced and metastatic solid tumors Meixia Chen, Yao Wang, Zhiqiang Wu, Hanren Dai, Can Luo, Yang Liu, Chuan Tong, Yelei Guo, Qingming Yang, Weidong Han A16 Cancer immunotherapy biomarkers: progress and issues Lisa H. Butterfield A17 Shaping of immunotherapy response by cancer genomes Timothy A. Chan A18 Unique development consideration for cancer immunotherapy Wenru Song A19 Immunotherapy combination Ruirong Yuan A20 Immunotherapy combination with radiotherapy Bo Lu A21 Cancer immunotherapy: past, present and future Ke Liu A22 Breakthrough therapy designation drug development and approval Max Ning A23 Current European regulation of innovative oncology medicines: opportunities for immunotherapy Harald Enzmann, Heinz Zwierzina

| S-EPMC5073990 | biostudies-literature

Abstracts of Poster Presentations: MauiDerm 2016 : January 25–29, 2016 • Grand Wailea • Maui, Hawaii

Project description: Not available

| S-EPMC5395239 | biostudies-literature

Metabolism and biological activity of 25-fluorocholecalciferol, 24-dehydrocholecalciferol and 25-dehydrocholecalciferol in the rat.

Project description:Three side-chain analogues of cholecalciferol (vitamin D3) modified at C-25, namely 25-fluorocholecalciferol, 24-dehydrocholecalciferol and 25-dehydrocholecalciferol, conceived as potential inhibitors of the cholecalciferol 25-hydroxylase have been prepared and tested in the rat. These compounds markedly diminish conversion in vivo of cholecalciferol into 25-hydroxycholecalciferol, but are not antagonists of vitamin D action, because they themselves possess significant biological activity in vivo. Each compound is capable of stimulating the intestinal transport of calcium and the mobilization of calcium from bone in vitamin D-deficient rats. Biological responses equivalent to those generated by a physiological dose of cholecalciferol (0.05 microgram) are produced, however, only when the analogues are administered at high doses (5-50 microgram). The biological activity of 24-dehydrocholecalciferol and 25-dehydrocholecalciferol is shown to result from conversion, in vivo, to the natural hormone, 1 alpha,25-dihydroxycholecalciferol, whereas 25-fluorocholecalciferol is metabolically activated in the rat by hydroxylation to 1 alpha-hydroxy-25-fluorocholecalciferol. This latter conversion is the first reported example of the 1 alpha-hydroxylation of a vitamin D compound lacking the 25-hydroxy group.

| S-EPMC1161227 | biostudies-other

The Pulse of Asia 2016 Seoul, September 24-26, 2016, Seoul, Republic of Korea: Abstracts

Project description: Not available

| S-EPMC5396454 | biostudies-literature

Analysis of Retinoblastoma Transcriptome

Project description:In this data, we examined Transcriptome detection and expression in 8 samples of Retinoblastoma. We found a central core shared by all samples . We used exon arrays to find a detected and undetected transcripts and genes in Retinoblastoma and we compared unilateral and bilateral samples.

2020-06-02 | GSE141209 | GEO

VUmc - CCA Genome Core

Project description:Organisation EGAO00000000238

| EGAO00000000238 | EGA

ena-DATASET-VUMC-CCA-09-06-2021-12:09:19:673-784 - samples

Project description:Shallow WGS of neuroblastoma cell lines with large-scale deletions induced through CRISPR-Cas9 and matching controls. Deletion of 11q was induced in the cell line SKNSH and loss of 6q was induced in the cell line NMB.

| EGAD00001007758 | EGA

mRNA sequencing time course of C. elegans samples at time point 1 hours until time point 24 hours at 25 degrees [N2 control]

Project description:We find gene expression oscillations which arise after a time lag of around 5 hours.

2020-07-27 | GSE141514 | GEO